<?xml version="1.0" encoding="UTF-8"?><xml><records><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Schott, Gisela</style></author><author><style face="normal" font="default" size="100%">Pachl, Henry</style></author><author><style face="normal" font="default" size="100%">Limbach, Ulrich</style></author><author><style face="normal" font="default" size="100%">Gundert-Remy, Ursula</style></author><author><style face="normal" font="default" size="100%">Ludwig, Wolf-Dieter</style></author><author><style face="normal" font="default" size="100%">Lieb, Klaus</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">The Financing of Drug Trials by Pharmaceutical Companies and its Consequences: Part 1: A Qualitative, Systematic Review of the Literature on Possible Influences on the Findings, Protocols, and Quality of Drug Trials</style></title><secondary-title><style face="normal" font="default" size="100%">Deutsches Ärzteblatt International</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2010</style></year></dates><urls><web-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2868984/</style></url></web-urls></urls><volume><style face="normal" font="default" size="100%">107</style></volume><pages><style face="normal" font="default" size="100%">279</style></pages><language><style face="normal" font="default" size="100%">eng</style></language></record></records></xml>